Lunai Bioworks (NASDAQ:LNAI) and AngioSoma (OTCMKTS:SOAN) Critical Review

AngioSoma (OTCMKTS:SOAN) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Risk and Volatility

AngioSoma has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares AngioSoma and Lunai Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioSoma	N/A	N/A	-1,245.34%
Lunai Bioworks	N/A	-378.07%	-210.59%

Analyst Ratings

This is a breakdown of current ratings for AngioSoma and Lunai Bioworks, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioSoma	0	0	0	0	0.00
Lunai Bioworks	1	0	0	0	1.00

Given AngioSoma’s higher probable upside, equities research analysts plainly believe AngioSoma is more favorable than Lunai Bioworks.

Valuation and Earnings

This table compares AngioSoma and Lunai Bioworks”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A
Lunai Bioworks	N/A	N/A	-$178.01 million	($0.07)	-13.71

Insider and Institutional Ownership

0.0% of AngioSoma shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lunai Bioworks beats AngioSoma on 5 of the 8 factors compared between the two stocks.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.